Skip to content
value.today

Swift Biosciences, Inc.

🇺🇸 Ann Arbor, Michigan, USABiotechnologyFounded 2009
Total raised
$28 M
5 rounds on record
Latest round
$4 M
Nov 2018
First round on record
Oct 2013
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Swift Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$4 MNo. 5$2 to $10 million

Swift Biosciences, Inc.: Raise no. 5, Nov 2018

Investors in this round

33 investors had bought by the notice of Nov 13, 2018: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $7 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Nathan Wood · Executive Officer, Director
  • Dan Kidle · Director
  • Dan Watkins · Director
  • Jack Ball · Director
  • Linda Tufts · Director
  • Mark Lewis · Director
  • Walter Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nathan Wood, President. Source: SEC Form D, newest notice filed Nov 13, 2018. Read the notice at the SEC.

equitySEC
May 2017$12 MNo. 4$10 to $50 million

Swift Biosciences, Inc.: Raise no. 4, May 2017

Investors in this round

38 investors had bought by the notice of Jun 12, 2017: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Halverson · Executive Officer
  • Timothy Harkins, PhD · Executive Officer, Director
  • Dan Kidle · Director
  • Dan Watkins · Director
  • Jack Ball, Jr. · Director
  • Mark Lewis · Director
  • Peter Kleinhenz · Director
  • Walter Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric Halverson, Treasurer. Source: SEC Form D, newest notice filed Jun 12, 2017. Read the notice at the SEC.

equitySEC
Apr 2016$3 MNo. 3$2 to $10 million

Swift Biosciences, Inc.: Raise no. 3, Apr 2016

Investors in this round

31 investors had bought by the notice of Apr 27, 2016: 31 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric Halverson · Executive Officer
  • Timothy Harkins, PhD · Executive Officer, Director
  • Vladimir Makarov · Executive Officer, Director
  • Dan Watkins · Director
  • Jack Ball, Jr. · Director
  • Peter Kleinhenz · Director
  • Walter Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric Halverson, Treasurer. Source: SEC Form D, newest notice filed Apr 27, 2016. Read the notice at the SEC.

equity, optionsSEC
Sep 2015$2 MNo. 2Under $2 million

Swift Biosciences, Inc.: Raise no. 2, Sep 2015

Investors in this round

13 investors had bought by the notice of Sep 10, 2015: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$7,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Tim Harkins · Executive Officer, Director
  • Vladimir Makarov · Executive Officer, Director
  • Dan Watkins · Director
  • Jack Ball, Jr. · Director
  • Peter Kleinhenz · Director
  • Walter Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric Halverson, Authorized Signatory. Source: SEC Form D, newest notice filed Sep 10, 2015. Read the notice at the SEC.

equity, optionsSEC
Oct 2013$7 MNo. 1$2 to $10 million

Swift Biosciences, Inc.: Raise no. 1, Oct 2013

Investors in this round

11 investors had bought by the notice of Oct 16, 2013: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
$8,450
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Olson · Executive Officer, Director
  • Vladimir Makarov · Executive Officer, Director
  • Dan Watkins · Director
  • Jack Ball, Jr. · Director
  • Peter Kleinhenz · Director
  • Walter Young · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Olson, President & CEO. Source: SEC Form D, newest notice filed Oct 16, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Swift Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2018).

    SEC Form D · Nov 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2018

That is all the official record says: Swift Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Swift Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 38 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Swift Biosciences, Inc.
NameRoleNamed in
Nathan WoodExecutive officerNov 2018
Eric HalversonExecutive officerJun 2017
Timothy Harkins, PhDExecutive officerJun 2017
Vladimir MakarovExecutive officerApr 2016
Tim HarkinsExecutive officerSep 2015
David OlsonExecutive officerOct 2013
Dan KidleDirectorNov 2018
Dan WatkinsDirectorNov 2018
Jack BallDirectorNov 2018
Linda TuftsDirectorNov 2018
Mark LewisDirectorNov 2018
Nathan WoodDirectorNov 2018
Walter YoungDirectorNov 2018
Jack Ball, Jr.DirectorJun 2017
Peter KleinhenzDirectorJun 2017
Timothy Harkins, PhDDirectorJun 2017
Vladimir MakarovDirectorApr 2016
Tim HarkinsDirectorSep 2015
David OlsonDirectorOct 2013